(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Exposure to neighborhood violence leads some Denver teens to use tobacco and alcohol earlier, new study shows - 2Most loved Specially prepared Espresso Mix: Which Meal Do You Adore the Most?
- 3Turkey, Egypt, Qatar discuss second phase of Gaza ceasefire deal
- 4November Lease Deals for the 2025 Kia EV6 are Too Good to Pass Up
- 5Tremendous Spelunking: Cool Caverns All over the Planet
- No red, no long shorts: The fashion rules Joe Burrows lives by
- PHOTO ESSAY: Summer camp for kids with autoimmune diseases
- The Best Games Crossroads in History
- Flourishing as a Charitable Pioneer: Individual Encounters in Generosity
- Courageous Climbing: Trails and Stuff for Outside Lovers
- Dr. Vinay Prasad's memo raises concerns about COVID-19 vaccines and pediatric mortality
- Find the Captivating Professional flowerbeds of the US
- Eating ultra-processed foods could raise precancerous polyp risk for women under 50, according to research
- Watching ‘Home Alone’ with the kids this holiday season? Brace yourself for '6-7.'
